Fifty 1 Labs, Inc. Celebrates Groundbreaking SpaceX, NASA, and ISS Yeast Experiment by Subsidiary Genetic Networks
Fifty 1 Labs (FITY) announces a major space research breakthrough through its subsidiary Genetic Networks, featuring groundbreaking yeast experiments on the recent SpaceX Fram2 mission. Led by Dr. Corey Nislow, the research builds on over a decade of space-based functional genomics, from the final Space Shuttle mission to Artemis I.
The latest experiment, launched on SpaceX's Fram2 mission, involves yeast strains engineered with tardigrade-derived transgenes to study their response to microgravity and cosmic radiation. This research aims to advance applications in human radiation therapy, particularly for cancer treatments.
Dr. Nislow's work focuses on understanding life's adaptation to space conditions, with implications for pharmaceutical development and space exploration. Genetic Networks plans to expand its SpaceX collaboration with multiple missions scheduled for 2025 and beyond, strengthening Fifty 1 Labs' position in biotechnology innovation both on Earth and in space.
Fifty 1 Labs (FITY) annuncia una significativa scoperta nella ricerca spaziale attraverso la sua controllata Genetic Networks, con esperimenti innovativi sui lieviti durante la recente missione Fram2 di SpaceX. Guidata dal Dr. Corey Nislow, la ricerca si basa su oltre un decennio di genomica funzionale spaziale, dalla missione finale dello Space Shuttle ad Artemis I.
L'ultimo esperimento, lanciato con la missione Fram2 di SpaceX, coinvolge ceppi di lievito ingegnerizzati con trasgeni derivati dai tardigradi per studiare la loro risposta alla microgravità e alla radiazione cosmica. Questa ricerca mira a migliorare le applicazioni nella terapia radiante umana, in particolare per i trattamenti contro il cancro.
Il lavoro del Dr. Nislow si concentra sulla comprensione dell'adattamento della vita alle condizioni spaziali, con implicazioni per lo sviluppo farmaceutico e l'esplorazione spaziale. Genetic Networks prevede di espandere la sua collaborazione con SpaceX con più missioni programmate per il 2025 e oltre, rafforzando la posizione di Fifty 1 Labs nell'innovazione biotecnologica sia sulla Terra che nello spazio.
Fifty 1 Labs (FITY) anuncia un importante avance en la investigación espacial a través de su subsidiaria Genetic Networks, con experimentos innovadores sobre levaduras en la reciente misión Fram2 de SpaceX. Dirigida por el Dr. Corey Nislow, la investigación se basa en más de una década de genómica funcional espacial, desde la última misión del transbordador espacial hasta Artemis I.
El último experimento, lanzado en la misión Fram2 de SpaceX, involucra cepas de levadura diseñadas con transgenes derivados de tardígrados para estudiar su respuesta a la microgravedad y la radiación cósmica. Esta investigación tiene como objetivo avanzar en las aplicaciones en terapia de radiación humana, particularmente para tratamientos contra el cáncer.
El trabajo del Dr. Nislow se centra en comprender la adaptación de la vida a las condiciones espaciales, con implicaciones para el desarrollo farmacéutico y la exploración espacial. Genetic Networks planea expandir su colaboración con SpaceX con múltiples misiones programadas para 2025 y más allá, fortaleciendo la posición de Fifty 1 Labs en la innovación biotecnológica tanto en la Tierra como en el espacio.
Fifty 1 Labs (FITY)는 자회사 Genetic Networks를 통해 주요 우주 연구의 돌파구를 발표하며, 최근 SpaceX의 Fram2 미션에서 혁신적인 효모 실험을 진행했습니다. Dr. Corey Nislow가 이끄는 이번 연구는 마지막 우주 왕복선 미션부터 Artemis I까지의 10년 이상의 우주 기반 기능 유전체학을 바탕으로 하고 있습니다.
최근 SpaceX의 Fram2 미션에서 시작된 실험은 미세 중력과 우주 방사선에 대한 반응을 연구하기 위해 개량된 완두콩 유래 유전자 변형 효모 균주를 포함합니다. 이 연구는 특히 암 치료를 위한 인간 방사선 요법의 응용을 발전시키는 것을 목표로 하고 있습니다.
Dr. Nislow의 연구는 우주 조건에 대한 생명의 적응을 이해하는 데 중점을 두고 있으며, 이는 제약 개발 및 우주 탐사에 대한 함의를 갖습니다. Genetic Networks는 2025년 이후 여러 미션을 계획하여 SpaceX와의 협력을 확대할 예정이며, 이는 Fifty 1 Labs의 지구와 우주에서의 생명공학 혁신 위치를 강화하는 데 기여할 것입니다.
Fifty 1 Labs (FITY) annonce une avancée majeure dans la recherche spatiale par le biais de sa filiale Genetic Networks, avec des expériences révolutionnaires sur les levures lors de la récente mission Fram2 de SpaceX. Dirigée par le Dr. Corey Nislow, la recherche s'appuie sur plus d'une décennie de génomique fonctionnelle spatiale, depuis la dernière mission de la navette spatiale jusqu'à Artemis I.
Le dernier expérience, lancée lors de la mission Fram2 de SpaceX, implique des souches de levure modifiées avec des transgènes dérivés des tardigrades pour étudier leur réponse à la microgravité et aux radiations cosmiques. Cette recherche vise à faire progresser les applications en thérapie par radiation humaine, en particulier pour les traitements contre le cancer.
Le travail du Dr. Nislow se concentre sur la compréhension de l'adaptation de la vie aux conditions spatiales, avec des implications pour le développement pharmaceutique et l'exploration spatiale. Genetic Networks prévoit d'élargir sa collaboration avec SpaceX avec plusieurs missions programmées pour 2025 et au-delà, renforçant la position de Fifty 1 Labs dans l'innovation biotechnologique tant sur Terre que dans l'espace.
Fifty 1 Labs (FITY) kündigt einen bedeutenden Durchbruch in der Raumforschung durch ihre Tochtergesellschaft Genetic Networks an, die bahnbrechende Hefexperimente während der jüngsten SpaceX Fram2-Mission durchführt. Unter der Leitung von Dr. Corey Nislow basiert die Forschung auf über einem Jahrzehnt funktioneller Genomik im Weltraum, von der letzten Space Shuttle-Mission bis Artemis I.
Das neueste Experiment, das mit der Fram2-Mission von SpaceX gestartet wurde, beinhaltet Hefestämme, die mit von Tardigraden abgeleiteten Transgenen modifiziert wurden, um ihre Reaktion auf Mikrogravitation und kosmische Strahlung zu untersuchen. Diese Forschung zielt darauf ab, Anwendungen in der menschlichen Strahlentherapie, insbesondere bei der Krebsbehandlung, voranzutreiben.
Die Arbeit von Dr. Nislow konzentriert sich darauf, das Verständnis für die Anpassung des Lebens an die Bedingungen im Weltraum zu vertiefen, mit Auswirkungen auf die pharmazeutische Entwicklung und die Raumfahrt. Genetic Networks plant, die Zusammenarbeit mit SpaceX durch mehrere Missionen, die für 2025 und darüber hinaus geplant sind, auszubauen und damit die Position von Fifty 1 Labs in der biotechnologischen Innovation sowohl auf der Erde als auch im Weltraum zu stärken.
- None.
- None.
Groundbreaking Yeast Experiment from Dr. Nislow's lab on Last Night's SpaceX Fram2 Mission Advances Space-Based Biotechnology
MELBOURNE, Fla., April 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs, Inc. (Ticker: FITY), a forward-thinking leader in biotechnology and health innovation, proudly announces a significant milestone in space research achieved by its recently acquired subsidiary, Genetic Networks. This milestone stems from over a decade of space-based functional genomics from Dr. Corey Nislow's laboratory. Beginning with STS-135, the final Space Shuttle mission to the ISS, through a successful sample return following lunar orbit on Artemis I, reported by CBC News on January 18, 2023 (https://www.cbc.ca/news/canada/british-columbia/yeast-space-experiment-1.6711816), this work highlights the pivotal role of functional genomics in diverse aspects of human health and wellness.
"These experiments are crucial to build a solid foundation to understand how life can adapt to the stresses of space, including microgravity and cosmic radiation beyond our planet," Dr. Nislow stated, as quoted in the original CBC report. "The data we've gathered could unlock new pathways for pharmaceutical development and human health in space exploration." His leadership and innovative approach have solidified Genetic Networks' reputation as a pioneer in genetic profiling, a strength that now significantly enhances Fifty 1 Labs' capabilities following the acquisition.
Since integrating Genetic Networks into its portfolio, Fifty 1 Labs has gained not only cutting-edge technology but also the invaluable contributions of Dr. Nislow, whose work bridges terrestrial biotechnology with space exploration. His vision for leveraging genetic insights to solve complex biological challenges aligns seamlessly with Fifty 1 Labs' mission to advance human health. The yeast experiment's findings—made possible through Dr. Nislow's expertise—open doors to applications ranging from resilient biological systems for long-duration space missions to novel therapeutics for Earth-based medicine.
Looking ahead, Genetic Networks is expanding its collaboration with SpaceX, with multiple missions planned for 2025 and the years to come.
"We are thrilled to celebrate this achievement by Genetic Networks and to have Dr. Corey Nislow as a key part of our team through this acquisition," said Gennaro D'Urso, CEO of Fifty 1 Labs, Inc. "Corey's leadership in space genomics, combined with Genetic Networks' upcoming SpaceX missions, exemplifies the forward-thinking innovation we aim to champion at Fifty 1 Labs. His presence brings tremendous value, amplifying our ability to push the boundaries of biotechnology on Earth and beyond."
In the Nislow labs' latest experiment which launched last night on SpaceX's Fram2 mission, yeast strains were engineered to express transgenes derived from tardigrades, micro animals that are known for their extraordinary resistance to radiation, were flown to measure their response to microgravity and cosmic radiation. The data will inform terrestrial applications for these transgenes in humans, including those undergoing radiation-based cancer therapies.
Fifty 1 Labs, Inc. invites investors, researchers, and the public to follow its journey as it leverages this milestone to drive innovation.
Investor Relations
877-814-4188
ir@fifty1labs.com
Website: https://geneticnetworks.com/
About Fifty 1 Labs, Inc. (FITY)
Fifty 1 Labs, Inc. (Ticker: FITY) is a dynamic biotechnology company dedicated to advancing human health through innovative research and development. With a focus on cutting-edge solutions, Fifty 1 Labs integrates advanced scientific discoveries to address challenges in medicine, wellness, and beyond.
About Genetic Networks
Genetic Networks, a wholly owned subsidiary of Fifty 1 Labs, Inc., specializes in genetic profiling and bioinformatics, delivering transformative insights into biological systems. Led by experts like Dr. Corey Nislow, its contributions to space-based research and terrestrial applications position it as a key player in the future of biotechnology.
Safe Harbor Statement:
The information provided in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Identifiable by words such as "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, these statements may also be made in written or oral form in the company's filings with the U.S. Securities and Exchange Commission, OTC Markets, press releases, other written materials, or in oral statements made by its officers, directors, or employees to third parties. There can be no assurance that such statements will prove to be accurate. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Disclosure Statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the company's control. The company does not undertake any obligation to update publicly or to revise any statements in this release, whether as a result of new information, future events, or otherwise.
FAQ
What is the significance of FITY's latest SpaceX Fram2 mission experiment?
How many space missions has FITY's Genetic Networks completed?
What are the potential applications of FITY's space-based yeast research?
How does the Genetic Networks acquisition benefit FITY's biotechnology capabilities?
What are FITY's future plans for space-based research?
